Short Summary
The PTAB issued a Final Written Decision rejecting all claims (1-18) because the Petitioner failed to demonstrate unpatentability by a preponderance of the evidence. The Board adopted a nuanced claim construction from District Court, requiring specific elements like reversed reflection and double distance for 'mirror mimicking.'
Detailed Summary
In this IPR proceeding, the PTAB rejected claims 1 through 18 after finding that the Petitioner failed to meet its burden of proof regarding unpatentability. A key aspect of the decision involved claim construction; the Board adopted a District Court's interpretation of 'mirror mimicking,' defining it as requiring reversed reflection, roughly double distance, and same size. Although the Petitioner argued for obviousness based on combining references like Rosenberg and Nakazawa, the Board found that the prior art did not teach or suggest the critical limitation of varying the processing rate according to distance (step 1(h)).
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Google LLC et al. vs EyesMatch Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Catalyst OrthoScience Inc.vsShoulder Innovations, Inc.
Catalyst OrthoScience seeks a PTAB post‑grant review of Shoulder Innovations' reverse shoulder implant patent, arguing obviousness over multiple prior‑art references and indefiniteness of the term “central channel.” The petition also asserts that discretionary denial is unwarranted.
Guardant Health, Inc.vsCold Spring Harbor Laboratory
The PTAB denied Guardant Health's IPR challenge against Cold Spring Harbor Laboratory's patent, finding the petitioner failed to show a reasonable likelihood of prevailing on any challenged claims.
Imperative Care, Inc.vsInari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 hemostasis valve patent after Imperative Care demonstrated a reasonable likelihood of unpatentability on claims 1‑9.
Berkshire Hathaway Energy Company et al.vsMES, Inc.
Berkshire Hathaway Energy and its affiliates have filed a joint motion to terminate the IPR concerning patent 10,668,430 after reaching a settlement with Birchtech Corp. The Board is asked to dismiss the proceeding with respect to WEC Energy Group.
Bicara Therapeutics, Inc.vsThe John Hopkins University et al.
Bicara Therapeutics has filed a PTAB Post‑Grant Review petition seeking cancellation of all nine claims of Johns Hopkins' 2025 antibody‑fusion protein patent, alleging lack of written description, lack of enablement, and improper claim dependency.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.